Andrea S. Blevins Primeau, PhD, MBA

A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.

COVID-19 vaccination may reduce the risk of COVID-19 sequelae in patients with cancer, according to researchers.

A novel method of treating immune checkpoint inhibitor-associated myocarditis may decrease the risk of death from myotoxicity.

Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.

Adding chemotherapy to first-line treatment with gefitinib improves outcomes in patients who have EGFR-mutant non-small cell lung cancer with brain metastases, a phase 3 trial suggests.

Adding pembrolizumab to chemotherapy nearly doubles the 5-year overall survival rate in patients with advanced non-small cell lung cancer, phase 3 data suggest.

COVID-19 vaccines did not reduce the risk of severe COVID-19 among cancer patients who received radiation, CAR T-cell therapy, or HSCT.

Targeted therapies are underused in Medicaid patients with EGFR- or ALK-altered, metastatic non-small cell lung cancer, research suggests.

The combination of atezolizumab and bevacizumab appears effective as first-line treatment for patients with NSCLC and a high tumor mutation burden.

Performing liquid biopsy before tissue biopsy reveals more biomarkers in patients with non-small cell lung cancer, a study suggests.

Adding serplulimab to chemotherapy prolonged overall survival in patients with previously untreated, extensive-stage small cell lung cancer.

Pembrolizumab is a potential new treatment option for stage IB-IIIA non-small cell lung cancer after complete resection, according to researchers.

Many patients with advanced non-small cell lung cancer do not survive long enough to receive second-line therapy, a real-world study suggests.

Adjuvant osimertinib continues to demonstrate a disease-free survival benefit vs placebo in resected, stage IB-IIIA, EGFR-mutated non-small cell lung cancer.

The prevalence of metastatic cancers in the US has risen in recent years and will increase further by 2025, according to researchers.

A CT-based follow-up approach improved early detection of lung cancer recurrence and second primary lung cancers but did not improve survival.

Survivors of Hodgkin lymphoma may have a higher risk of developing lung cancer than former smokers, a study suggests.

Sintilimab, IBI305, and chemotherapy could be a new standard of care for patients with EGFR-mutant NSCLC that progressed on an EGFR TKI.

Detection of ctDNA and early changes in ctDNA levels may predict treatment outcomes in patients with advanced solid tumors.

Disparities in cancer diagnoses among pediatric patients are partly a result of disparities in health insurance coverage, a study suggests.

Blood type may influence response to immune checkpoint inhibitor therapy among patients with metastatic cancer, a study suggests.

There were more than 18 million cancer survivors in the United States at the beginning of this year, according to new data.

Medicaid beneficiaries had a higher risk of death than commercially-insured patients, but the risk of death decreased if Medicaid beneficiaries underwent biomarker testing.